Zelda Provides CannPal Priority Share Offer Clarification Announcement

By:
Zelda Provides CannPal Priority Share Offer Clarification Announcement

PERTH, Australia, August 31, 2017 /Weed Wire/ — Further to the ASX announcement dated 29 August 2017 title ‘Priority Share Offer for CannPal Animal Therapeutics Ltd IPO Shares’, the Board of Zelda Therapeutics Ltd (ASX: ZLD, Zelda or the Company) wishes to clarify the Priority Offer Record Date.

Under the CannPal Animal Therapeutics Ltd (‘CannPal’) Prospectus, 5,000,000 fully paid ordinary shares (Shares) at $0.20 per Share have been allocated and made available to those ZLD shareholders registered on 4 September 2017 holding a minimum of 25,000 ZLD shares (Eligible ZLD Shareholders) collectively on a priority application basis.

Tim Slate
Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)
Zelda Therapeutics (“Zelda”) is an Australian-based bio-pharmaceutical company that is focused on
developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:
• A human clinical trial programme focused on insomnia, autism and eczema with activities in Australia and Chile.
• A pre-clinical research programme examining the effect of cannabinoids in breast, brain and pancreatic cancer. It has partnered with the world’s leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis- based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.
The Company has secured certain rights to medicinal cannabis based formulations and treatment protocols developed over many years by a California-based group (Aunt Zelda’s) that has a very high profile within the USA and a growing international profile.

ZELDA THERAPEUTICS LIMITED ACN 103 782 378
Level 45
108 St Georges Terrace, Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
Web: www.zeldatherapeutics.com

Contacts Corporate
Mr Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Investors
Dr Stewart Washer
Executive Director
+61 418 288 212
swasher@zeldatherapeutics.com

Weed Wire disseminates press releases from companies and organizations in the legal marijuana industry. Email weedwire@mjic.com to have your press release added.

Top